Puma Biotech shares slide after glimpse of trial data on cancer drug | Financial Times
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire
Puma Biotechnology
Jobs with Puma Biotechnology
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotech plunges on drug side effects
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotech Gets $100M Loan to Boost Breast Cancer Drug - Los Angeles Business Journal
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Takeda farms out cancer drug alisertib to Puma Biotech -
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology, Inc. | LinkedIn
PumaBiotech (@pumabiotech) / Twitter
Why Puma Biotechnology Shares Dropped 17.7% This Week | The Motley Fool
